Arcus Biosciences Q3 2026 Results: Collaboration Revenue Falls as Loss Narrows

Arcus Biosciences (NYSE: RCUS) reported Q3 2026 revenue of $9 million, down from $26 million a year earlier, while its basic and diluted GAAP net loss per share improved to $1.00 from $1.27. Lower R&D and administrative expenses narrowed the net loss, while casdatifan clinical data and upcoming Phase 3 milestones remained the main operational focus.

Core Financial Results

Revenue fell by approximately 65% as activities under the Gilead collaboration wound down or reached completion. Higher revenue associated with programs under the Taiho collaboration provided only a partial offset.

The lower revenue did not lead to a wider quarterly loss because total operating expenses declined by $28 million. Net loss narrowed to $128 million from $135 million.

The per-share loss improved more than the net loss because the weighted-average basic and diluted share count increased to 127.4 million from 106.5 million.

Pipeline and Clinical Progress

Casdatifan, Arcus’s HIF-2α inhibitor for clear cell renal cell carcinoma, remains the centerpiece of the pipeline. The October ARC-20 update included results across first-, second- and late-line treatment settings, although the company’s comparisons with external benchmarks were not based on head-to-head trials.

No unexpected safety signals were observed across the cohorts as of the September 4, 2026 data cutoff. However, casdatifan remains investigational, and the reported cohort results do not establish regulatory approval or commercial viability.

Enrollment in PEAK-1, the Phase 3 trial of casdatifan plus cabozantinib in second-line disease, is expected to finish within two to three months of the update. Arcus also plans to initiate PEAK-20, evaluating casdatifan with ipilimumab and nivolumab in first-line disease, by the end of 2026. More mature survival data and early results from additional combinations are expected in 2027.

Outside casdatifan, an interim analysis of the fully enrolled Phase 3 PRISM-1 study of quemliclustat in first-line metastatic pancreatic cancer is scheduled for Q4 2026. Arcus also began a first-in-human study of AB102 in August 2026 and expects several additional immunology candidates to potentially enter clinical development in 2027.

Lower Expenses More Than Offset the Revenue Decline

The $28 million reduction in operating expenses was larger than the $17 million revenue decline, allowing the operating loss to narrow by $11 million. R&D spending decreased primarily because Arcus wound down Phase 2 and Phase 3 domvanalimab studies and completed enrollment in PRISM-1. Streamlining and efficiencies across other programs also contributed.

These savings were partially offset by increasing investment in casdatifan Phase 3 development. Gross collaboration reimbursements also fell to $12 million from $28 million as Arcus shifted toward programs that it funds fully. Management expects near-term R&D expense to remain relatively consistent as casdatifan and immunology investment offsets reductions elsewhere.

Liquidity and Balance Sheet

Cash, cash equivalents and marketable securities declined to $694 million at September 30, 2026, from $1.01 billion at December 31, 2025—a decrease of $316 million, or approximately 31%. Arcus attributed the decrease primarily to cash used for R&D activities.

After the quarter ended, the company raised $288 million in gross proceeds through an October equity financing. Arcus said its quarter-end liquidity, together with those proceeds, should fund planned operations into 2029 under its existing business plan.

Guidance

Arcus expects full-year 2026 GAAP revenue of $70 million to $75 million. Its liquidity outlook depends on the current development plan and the expected pace of spending across casdatifan and other programs.

Recent Insider Transactions

The supplied insider data show 81,867 shares categorized as purchases and 113,152 shares categorized as sales over the preceding six months, resulting in net sales of 31,285 shares. That net amount represented approximately 0.10% of the 32.55 million shares held by insiders.

The 10 most recent entries included three sales, one derivative-security conversion and six director stock grants. These transactions are presented objectively and do not by themselves indicate insiders’ views of the company’s prospects.

Risks Investors Need to Watch

• Clinical results may not be replicated in Phase 3 trials. The ARC-20 findings came from cohorts with different sizes and follow-up periods, while pivotal PEAK-1 and PEAK-20 outcomes remain pending.
• External benchmark comparisons have limitations. Arcus’s comparisons with other regimens were not head-to-head and may be affected by differences in trial design, patient populations and eligibility criteria.
• Collaboration revenue is declining. The wind-down or completion of Gilead-related activities reduced quarterly revenue substantially, increasing the importance of future collaboration revenue and pipeline execution.
• Development spending remains significant. Quarter-end liquidity fell by $316 million from the end of 2025, and investment in casdatifan and immunology programs is expected to offset savings from discontinued or completed studies.
• Trial timelines carry execution risk. Delays in enrollment, site activation, regulatory review, manufacturing or drug supply could affect planned Phase 3 starts, completion dates and 2027 data readouts.

Summary

Arcus’s Q3 2026 results combined a sharp decline in collaboration revenue with lower operating expenses, producing a modestly narrower net loss. The company’s investment case remains closely tied to casdatifan: upcoming Phase 3 execution and more mature survival data will be central to assessing whether the encouraging ARC-20 findings can be reproduced in registrational studies. The October financing extends the expected runway into 2029, but clinical spending and declining collaboration revenue remain important areas to monitor.